This is a synthetic peptide designed for use in combination with anti-TP63 antibody (Catalog #: ARP33998_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
TP63
Reaktivität: Human, Maus, Ratte
Wirt: Synthetic
BP, BI
Applikationshinweise
Each Investigator should determine their own optimal working dilution for specific applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Konzentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
p63 (TP63)
(Tumor Protein P63 (TP63))
Hintergrund
This protein plays in the development and maintenance of stratified epithelial tissues. p63 -/- mice have several developmental defects which include the lack of limbs and other tissues, such as teeth and mammary glands, which develop as a result of interactions between mesenchyme and epithelium. This gene encodes a member of the p53 family of transcription factors. An animal model, p63 -/- mice, has been useful in defining the role this protein plays in the development and maintenance of stratified epithelial tissues. p63 -/- mice have several developmental defects which include the lack of limbs and other tissues, such as teeth and mammary glands, which develop as a result of interactions between mesenchyme and epithelium. Mutations in this gene are associated with ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3), split-hand/foot malformation 4 (SHFM4), ankyloblepharon-ectodermal defects-cleft lip/palate, ADULT syndrome (acro-dermato-ungual-lacrimal-tooth), limb-mammary syndrome, Rap-Hodgkin syndrome (RHS), and orofacial cleft 8. Both alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different proteins. Many transcripts encoding different proteins have been reported but the biological validity and the full-length nature of these variants have not been determined.